The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 9
- 4 new, 5 renewals
- Median first-year cost
- $902,819
- $7,488,186 in all
- Institutions
- 8
- 9 contact PIs
- Patents
- 8
- from 3 funded projects
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- EMORY UNIVERSITY1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- H. LEE MOFFITT CANCER CTR & RES INST1
- UNIVERSITY OF MICHIGAN AT ANN ARBOR1
and 3 other institutions
Most frequent study sections
- Special Emphasis Panel (ZCA1 RPRB-B (A1))9
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2016 | Great Lakes New England Clinical Validation Center2U01CA086400-16 | Brenner, Dean E. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | First-year cost $1,374,531 | Study section ZCA1 |
| FY2016 | Breast, Colorectal, and Ovary Cancer Clinical Validation Center2U01CA152637-06 | Drescher, CharlesLampe, Paul D.Li, Christopher I | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | First-year cost $1,011,430 | Study section ZCA1 |
| FY2016 | MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer1U01CA200462-01 | Bast, Robert C | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $951,958 | Study section ZCA1 |
| FY2016 | Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center2U01CA113913-11 | Sanda, Martin G. | EMORY UNIVERSITY, GA | First-year cost $930,297 | Study section ZCA1 |
| FY2016 | Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms1U01CA200466-01 | Batra, Surinder K.Brand, Randall | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | First-year cost $902,819 | Study section ZCA1 |
| FY2016 | A Clinical Validation Center for Early Detection of Pancreatic Cancer1U01CA200468-01 | Maitra, Anirban | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $794,418 | Study section ZCA1 |
| FY2016 | Validation of Biomarkers of Risk for the Early Detection of Lung Cancer2U01CA152662-06 | Massion, Pierre P. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | First-year cost $715,735 | Study section ZCA1 |
| FY2016 | Moffitt Imaging Biomarker VAlidation Center1U01CA200464-01 | Gillies, Robert J.Heine, John JLee, Jae K.Schabath, Matthew B. | H. LEE MOFFITT CANCER CTR & RES INST, FL | First-year cost $706,998 | Study section ZCA1 |
| FY2016 | San Antonio Center for Biomarkers of Risk for Prostate Cancer (SABOR)2U01CA086402-16 | Leach, Robin JeanThompson, Ian M. | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | First-year cost $100,000 | Study section ZCA1 |
Patents from its funded projects
8 patents name 3 of the 9 funded projects. The newest 5, by patent number.
- US 12,498,372 (opens the patent at USPTO, a PDF, in a new tab)BIOMARKER FOR DETECTING CANCERGranted December 16, 2025 to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMU01CA086400 · UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI
- US 10,815,484 (opens the patent at USPTO, a PDF, in a new tab)Compositions and Methods for Treating CancerGranted October 27, 2020 to THE REGENTS OF THE UNIVERSITY OF MICHIGANU01CA113913 · EMORY UNIVERSITY, GA
- US 10,774,122 (opens the patent at USPTO, a PDF, in a new tab)ERG TARGETED THERAPYGranted September 15, 2020 to THE REGENTS OF THE UNIVERSITY OF MICHIGANU01CA113913 · EMORY UNIVERSITY, GA
- US 10,725,053 (opens the patent at USPTO, a PDF, in a new tab)PANEL OF PROSTATE CANCER-ASSOCIATED SECRETED PROTEINS FOR DIAGNOSIS AND PROGNOSISGranted July 28, 2020 to Battelle Memorial Institute and University of WashingtonU01CA086402 · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX
- US 10,620,206 (opens the patent at USPTO, a PDF, in a new tab)BIOMARKER FOR DETECTING CANCERGranted April 14, 2020 to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMU01CA086400 · UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.